ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Recent advances and application of SFC-MS in small molecules drug discovery

4th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Gerard Rosse

ScientificTracks Abstracts: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.013

Abstract
The structure guided chemistry department has implemented innovative technologies to design, synthesize and purify target focused compound libraries with the mission of enabling discovery of novel druglike leads. Compound purification and the subsequent structure validation are critical steps for successful lead identification and lead optimization campaigns. Supercritical fluid chromatography-mass spectrometry (SFC-MS) technology has gained wide acceptance for achiral purification in drug discovery research. The emerging instrumentation, techniques and processes for analytical and preparative SFC-MS will be discussed. Comparative studies for the application of HPLC and SFC techniques in a high throughput environment will also be presented
Biography
Gerard Rosse has been involved in drug discovery research and development for more than 15 years. He is currently Associate Director, Structure Guided Chemistry, at Dart Neuroscience and also serves as Adjunct Associate Professor at Drexel University as well as Adjunct Professor in Medicinal Chemistry at the Pennsylvania Drug Discovery Institute. Prior he functioned in leadership and scientific positions in medicinal chemistry with Cephalon, Sanofi and F. Hoffman-La Roche. During his industrial tenure, he led multidisciplinary teams and invented multiple pre-clinical candidates and compound lead series spanning a wide range of therapeutic indications. These include CNS (cognition, schizophrenia, alzheimer?s disease), inflammation, metabolism, oncology, cardiovascular disease and antibacterial agents. His career is also characterized by implementation of innovative high throughput technology platforms in the area of small molecules and peptides drug discovery, analytical chemistry and data management that increased productivity and accelerated the drug discovery process. He is a distinguished speaker at business meetings in US and Europe and has authored 40+ patents and publications. He received the Ph.D. degree in chemistry from the University of Basel in Switzerland and postdoctoral training at Stanford University.
Top